Crystal MD - Lyell Immunopharma Founder Advisor
| LYEL Stock | USD 0.95 0.03 3.26% |
Insider
Crystal MD is Founder Advisor of Lyell Immunopharma
| Age | 63 |
| Address | 201 Haskins Way, South San Francisco, CA, United States, 94080 |
| Phone | 650 695 0677 |
| Web | https://lyell.com |
Lyell Immunopharma Management Efficiency
The company has return on total asset (ROA) of (0.1912) % which means that it has lost $0.1912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3322) %, meaning that it created substantial loss on money invested by shareholders. Lyell Immunopharma's management efficiency ratios could be used to measure how well Lyell Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.33. The value of Return On Capital Employed is expected to slide to -0.36. At this time, Lyell Immunopharma's Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 1 B this year, although the value of Other Assets will most likely fall to about 4.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Hennie Hoogenboom | Merus BV | N/A | |
| Sven MD | Merus BV | 61 | |
| Ralph Brandenberger | Nkarta Inc | 55 | |
| Matthew Stanton | Generation Bio Co | 51 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Jillian Connell | Merus BV | N/A | |
| Path FRCP | Revolution Medicines | 61 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Joshua Kazam | Kronos Bio | 47 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Cameron MD | Generation Bio Co | 54 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Cornelis Kruif | Merus BV | 59 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Kenneth JD | Century Therapeutics | N/A | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 |
Lyell Immunopharma Leadership Team
Elected by the shareholders, the Lyell Immunopharma's board of directors comprises two types of representatives: Lyell Immunopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lyell. The board's role is to monitor Lyell Immunopharma's management team and ensure that shareholders' interests are well served. Lyell Immunopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lyell Immunopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Homans, CEO Director | ||
| Richard Goold, Chief Officer | ||
| Stephen Hill, Chief Officer | ||
| Crystal MD, Founder Advisor | ||
| Charles Newton, Chief Officer | ||
| Prof MD, Founder Advisor | ||
| Nellie Dillery, Director Accounting | ||
| Matthew JD, Chief Officer | ||
| Gary Lee, Chief Officer | ||
| Ellen Rose, Senior Relations | ||
| Richard MD, Founder Chairman | ||
| Lynn MD, CEO President |
Lyell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lyell Immunopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (133.17 M) | ||||
| Shares Outstanding | 279.22 M | ||||
| Shares Owned By Insiders | 14.06 % | ||||
| Shares Owned By Institutions | 61.64 % | ||||
| Number Of Shares Shorted | 11.14 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 4,062 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.